Thus, 89Zr-PD-1 IgG PET could be useful for monitoring tumor-expressed PD-1, which in turn may help lead to more rational application of immune checkpoint therapies for T-cell lymphomas. This evidence concerns the gene PDCD1 and T-cell non-Hodgkin lymphoma.